NVAX logo

NOVAVAX INC

NVAXNASDAQ
🏆 #2084 by market capEarnings Nov 4US Equity
$379.35▲ $20.11 (+5.30%)
Simulated price
🔔
Track NVAX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.3%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.78B
Small Cap
📈Revenue Growth (YoY)
+64.7%
High Growth
📊Gross Margin
77.8%
High
💵FCF Margin
-10.5%
Thin
⚖️P/S Ratio
4.3x
Fair
Otter Score
60
Fair
No chart data available for NVAX.

Trading Snapshot

Day Range
$373.61 – $385.18
52-Week Range
$6.20 – $11.97
Volume
$1.72B
Avg Volume
$2.12B
Shares Outstanding
164.4M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$1.12B
Last Q Revenue
$57M
P/E Ratio
-7.1
P/S Ratio
4.3x
EPS (TTM)
$-1.51
Dividend Yield
0.00%
Dilution (1yr)
+8.0%

Why Investors Own NVAX

  • ✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 49% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NVAX logo

NOVAVAX INC

NVAX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.1B▲ +64.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.7%▲ +33.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$563M▼ −326.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$250M▲ +149.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
173.1M▲ +8.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$8M▼ −$308M YoY
StockOtter · stockotter.space

About NOVAVAX INC

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$416.81
▲ +9.9% Upside
High Target$451.60
Low Target$375.36
Based on 12 analysts

Latest News & Updates

🚀
Reuters·2h ago

NOVAVAX INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift NVAX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

NOVAVAX INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.